ArticleClinical ophthalmology (Auckland, N.Z.)2025
A 12-Month Multicenter Postmarketing Clinical Study of a Trifocal Intraocular Lens in a Chinese Population.
Article in Clinical ophthalmology (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This 12-month, prospective, single-arm, postmarketing study assessed efficacy, safety, and patient satisfaction for AcrySof IQ PanOptix TFNT00 intraocular lens in a Chinese population. Patients and Methods: Adults with bilateral cataracts received TFNT00 (286 eyes); visual acuity (VA) was assessed at 12 months. Manifest refraction spherical equivalent (MRSE), corrected and uncorrected distance VA (CDVA, UDVA), distance-corrected and uncorrected intermediate (DCIVA, UIVA) and near (DCNVA, UNVA) VA, and defocus curve were evaluated. Patient-reported outcomes were assessed using questionnaires. Adverse events (AEs) were evaluated. Results: 134/144 patients (268/286 eyes) completed the study. At 12 months, MRSE was -0.06±0.36 D. Monocular and binocular CDVA ≤0.3 logMAR was achieved in 99.3% of patients. Mean±SD monocular CDVA, UDVA, DCIVA, UIVA, DCNVA, and UNVA were -0.01±0.13, 0.04±0.13, 0.076±0.14, 0.089±0.14, 0.084±0.13, and 0.096±0.13 logMAR, respectively. Binocular VA was equal to or better than 0.1 logMAR for defocus range +0.5 to -3.0 D. Most patients achieved spectacle independence for distance (94%), intermediate (90%), and near (87%) vision; 88% were "satisfied" or "very satisfied." No device-related AEs were reported. Forty eyes (14%) had posterior capsular opacity (37 were clinically nonsignificant; 1 [0.4%] required posterior capsulotomy). Five cystoid macular edema cases (1.7%) were reported. Severe starbursts, halo, and glare were reported by 15.6%, 4.4%, and 2.3% of patients, respectively, with only 1.5% of patients significantly bothered by each. Conclusion: TFNT00 was safe and effective in a Chinese population, providing good VA at far, intermediate, and near distances, with high rates of spectacle independence and patient satisfaction.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.